Nature Reviews Drug Discovery
@natrevdrugdiscov.nature.com
4.7K followers 52 following 210 posts
Editorial team of Nature Reviews Drug Discovery www.nature.com/nrd
Posts Media Videos Starter Packs
Reposted by Nature Reviews Drug Discovery
markfortner.bsky.social
#Cachexia is a common co-morbidity in a number of late stage cancers. It’s frequently seen in #PancreaticCancer. Most drug discovery companies are focused on treating the cancer itself, but late stage disease is often so biologically complex that this is a bit like banging your head against a wall.
natrevdrugdiscov.nature.com
Cancer cachexia contender enters first pivotal trial www.nature.com/articles/d41...

Can Pfizer’s appetite-boosting antibody ponsegromab address a cancer-induced wasting syndrome — and help patients live longer in the process? Find out more in this news article #CancerGrandChallenges
Screenshot of story
natrevdrugdiscov.nature.com
Cancer cachexia contender enters first pivotal trial www.nature.com/articles/d41...

Can Pfizer’s appetite-boosting antibody ponsegromab address a cancer-induced wasting syndrome — and help patients live longer in the process? Find out more in this news article #CancerGrandChallenges
Screenshot of story
natrevdrugdiscov.nature.com
Novo Nordisk's $4.7 billion upfront purchase of Akero to gain its FGF21 analogue for MASH today follows Roche's potential $3.5 billion deal around a similar drug from 89bio last month www.nature.com/articles/d41...
Read more about FGF21 analogues in this review rdcu.be/eKbyo
Screenshot of news story
natrevdrugdiscov.nature.com
Genmab nabs EGFR × LGR5 bispecific in US$8 billion Merus acquisition www.nature.com/articles/d41...

For readers interested in bispecific antibodies in oncology, here's a comprehensive review rdcu.be/eJ2XM
www.nature.com/articles/s41...
natrevdrugdiscov.nature.com
Our latest research highlight covers a paper in Cell on the computational de novo design of a peptide modulator that addresses voltage-gated sodium channel dysfunction linked to epilepsy and cardiac arrhythmias nature.com/articles/d41...
Designer peptide retunes channel function
Discover the world’s best science and medicine | Nature.com
nature.com
natrevdrugdiscov.nature.com
Today's Nobel Prize for Physiology or Medicine relates to research on regulatory T cells www.nobelprize.org/prizes/medic...

For readers interested in harnessing the biology of regulatory T cells to treat disease, here's a comprehensive review www.nature.com/articles/s41...
rdcu.be/eJHU8
Regulatory T cell biology
natrevdrugdiscov.nature.com
Our October issue is live! Read more about targeting protein disorder in drug discovery, metabolites as agents and targets for cancer immunotherapy, targeting DNA damage in ageing and more here www.nature.com/nrd/volumes/...
October issue contents
Reposted by Nature Reviews Drug Discovery
natrevdrugdiscov.nature.com
In vivo CAR-T cell therapy
www.nature.com/articles/s41...
rdcu.be/eI7zH
This new Review discusses how technological advances that remove the need for ex vivo manipulation and chemotherapeutic conditioning could enable wider application of CAR-T cell therapies in blood cancers and autoimmune diseases
natrevdrugdiscov.nature.com
This new article analyses the evolution of the pipeline and market for obesity drugs, which is being transformed by GLP-1-based therapies www.nature.com/articles/d41...
The obesity drug market
natrevdrugdiscov.nature.com
Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities
www.nature.com/articles/s41...
rdcu.be/eHOJ9
This new Review discusses progress with drugs targeting inflammatory cytokines such as IL-4 and IL-5, neutrophils, alarmins and kinases
Drug targets for COPD
natrevdrugdiscov.nature.com
Our latest research highlight covers two papers reporting novel NLRP3 inhibitors for inflammatory diseases
www.nature.com/articles/d41...

For readers interested in the NRLP3 inflammasome as a therapeutic target, here's a review
www.nature.com/articles/s41...
rdcu.be/eHePm
Overcoming roadblocks to anti-inflammatory NLRP3 inhibitors
Discover the world’s best science and medicine | Nature.com
www.nature.com
Reposted by Nature Reviews Drug Discovery
fullrich.bsky.social
Join us for the 3rd Nature Conference on Nucleic Acid Medicines in Boston (Dec 8-10) with an amazing lineup of speakers. 4 weeks left 4 early bird registration! natureconferences.streamgo.live/cracking-the...
@natureportfolio.nature.com @nature.com @natbiotech.nature.com @natrevdrugdiscov.nature.com
Nature Conferences. Cracking the Code: Nucleic Acid Medicines Coming of Age. December 8 - 10, Boston, MA, United States. Organized by Alnylam, Ionis, HSCI, Boston Children’s Hospital, and Nature Portfolio Speakers include: Anna Pyle (Yale),’Arthur Krieg (Zola Therapeutics), Mano Manoharan (Alnylam), Grace Chen (Yale), Howard Chang (Stanford), Maria Barna (Stanford) - picture shows their portraits.
natrevdrugdiscov.nature.com
Breakthrough therapy designations in China and the United States www.nature.com/articles/d41...

This new article analyses breakthrough therapy programmes intended to help address unmet medical needs in the two countries
Breakthrough therapy designations in China and the United States
Discover the world’s best science and medicine | Nature.com
www.nature.com
natrevdrugdiscov.nature.com
Novel drug candidates for hard-to-treat hypertension vie for blockbuster positioning
www.nature.com/articles/d41...
natrevdrugdiscov.nature.com
New online: Synthetic lethality in cancer drug discovery: challenges and opportunities
www.nature.com/articles/s41...
rdcu.be/eFDCl
This Review discusses advances in the discovery and validation of synthetic lethal pairs, and the development of drugs that target them
History of synthetic lethality
natrevdrugdiscov.nature.com
Chemical modification and engineering approaches for guide RNAs can enhance or enable CRISPR-based therapies by addressing issues such as delivery, stability, editing efficiency and off-target effects - find out more in this review www.nature.com/articles/s41...
rdcu.be/eFb79
natrevdrugdiscov.nature.com
For readers interested in cancer therapies, this Review in our September issue discusses molecular pathways and effector functions by which neutrophils modulate cancer progression, and considers tractable therapeutic targets
www.nature.com/articles/s41...
rdcu.be/eEVmh
Targeting neutrophils in cancer